120 related articles for article (PubMed ID: 16873088)
1. Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease.
Principi M; Day R; Marangi S; Burattini O; De Francesco V; Ingrosso M; Pisani A; Panella C; Forbes A; Di Leo A; Francavilla A; Ierardi E
Immunopharmacol Immunotoxicol; 2006; 28(2):185-95. PubMed ID: 16873088
[TBL] [Abstract][Full Text] [Related]
2. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier.
Felwick RK; Dingley GJR; Martinez-Nunez R; Sanchez-Elsner T; Cummings JRF; Collins JE
J Crohns Colitis; 2020 Mar; 14(3):381-392. PubMed ID: 31626694
[TBL] [Abstract][Full Text] [Related]
4. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
[TBL] [Abstract][Full Text] [Related]
5. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Lundin M; Kokkola A; von Boguslawski K; Haglund C
Int J Cancer; 2001 Jan; 95(1):1-6. PubMed ID: 11241302
[TBL] [Abstract][Full Text] [Related]
6. Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.
Vaiphei K; Kumari N; Sinha SK; Dutta U; Nagi B; Joshi K; Singh K
World J Gastroenterol; 2006 Jun; 12(22):3602-8. PubMed ID: 16773719
[TBL] [Abstract][Full Text] [Related]
7. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium.
Soukka T; Pohjola J; Inki P; Happonen RP
J Oral Pathol Med; 2000 Aug; 29(7):308-13. PubMed ID: 10947246
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
9. Regulation of epithelial syndecan-1 expression by inflammatory cytokines.
Day RM; Mitchell TJ; Knight SC; Forbes A
Cytokine; 2003 Mar; 21(5):224-33. PubMed ID: 12824007
[TBL] [Abstract][Full Text] [Related]
10. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
[TBL] [Abstract][Full Text] [Related]
12. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia.
Cesaro A; Abakar-Mahamat A; Brest P; Lassalle S; Selva E; Filippi J; Hébuterne X; Hugot JP; Doglio A; Galland F; Naquet P; Vouret-Craviari V; Mograbi B; Hofman PM
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1332-43. PubMed ID: 19299578
[TBL] [Abstract][Full Text] [Related]
13. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease.
Woywodt A; Ludwig D; Neustock P; Kruse A; Schwarting K; Jantschek G; Kirchner H; Stange EF
Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):267-76. PubMed ID: 10333199
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
15. Localization of syndecan-1 in human gastric mucosa associated with ulceration.
Tanabe H; Yokota K; Kohgo Y
J Pathol; 1999 Feb; 187(3):338-44. PubMed ID: 10398089
[TBL] [Abstract][Full Text] [Related]
16. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
17. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
Lundin M; Nordling S; Lundin J; Isola J; Wiksten JP; Haglund C
Oncology; 2005; 68(4-6):306-13. PubMed ID: 16020957
[TBL] [Abstract][Full Text] [Related]
18. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T
Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
Griga T; May B; Pfisterer O; Müller KM; Brasch F
Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways.
Souza HS; Tortori CJ; Castelo-Branco MT; Carvalho AT; Margallo VS; Delgado CF; Dines I; Elia CC
Int J Colorectal Dis; 2005 May; 20(3):277-86. PubMed ID: 15503066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
